Studying the origins of childhood acute myeloid leukaemia to identify targets for kinder and more effective treatments
Learning more about leukaemia cells in order to design targeted treatments that can increase survivorship and quality of life.
We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Learning more about leukaemia cells in order to design targeted treatments that can increase survivorship and quality of life.
Looking for repurposed treatments that can fight leukaemia cells in very young children.
Looking at the early stages of leukaemia that develops after treatment for other cancers to find out what changes occur and how to fight it.
Investigating how a protein that causes relapse in acute myeloid leukaemia interacts with the genetic code, and whether these interactions could be prevented.
Understanding how leukaemia cells enlist immune system cells to help them survive chemotherapy.
Investigating how a protein changes the way leukaemia cells behave in babies.
Looking at how a process called 'cut-and-run' leads to genetic errors, and how those errors could be prevented in order to prevent relapse in childhood leukaemia.
Looking at a new subtype of leukaemia, called CML-like Ph+ALL, to see how best to diagnose and treat it.
Using models to find out how high risk leukaemia cells grow and become resistant to treatment.